Real-world data highlight tofacitinib potential for irAE management in cancer patients
19 Dec 2023
byAudrey Abella
In a study presented at ESMO Asia 2023, tofacitinib, a rapidly acting JAK-STAT inhibitor with reported efficacy in the treatment of various autoimmune diseases, was effective for the management of difficult-to-treat immune-related adverse events (irAEs) and was well-tolerated in cancer patients, with only a few patients developing infectious events.
